Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD985 plus Niraparib in HER2-expressing Solid Tumors
NCT04235101Phase 1Completed
- Sponsor
- Byondis
- Start
- Jun 2020
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab duocarmazine in solid tumor, breast cancer, ovarian cancer and 1 more, sponsored by Byondis. Primary endpoint: Incidence of Dose-Limiting Toxicities at 21 days. Started Jun 2020; status: completed.
02
Drugs
trastuzumab duocarmazine
03
Conditions
solid tumorbreast cancerovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT04235101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235101.